New filings, approvals and devices fuel Johnson & Johnson’s cancer ambitions

Johnson & Johnson is rapidly advancing its drug and device pipeline, highlighting oncology as a key growth engine. The company reported encouraging preliminary results in prostate cancer, filed for FDA approval of IMAAVY in warm autoimmune hemolytic anemia, and secured FDA approval for more convenient monthly RYBREVANT FASPRO dosing. Complementing its pharma moves, J&J expanded its interventional portfolio with new CEREGLIDE and INNERGLIDE catheters. Together, these developments underscore efforts to sustain double-digit oncology growth and broaden its presence across cancer care and adjacent specialties.